Pancreas cancer meets the thunder God

Science Translational Medicine

Volumn 4, Issue 156, 2012, Pages

  Hingorani, Sunil R ^a,b   Potter, John D ^a,c,d  

^a USA   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d MASSEY UNIVERSITY   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GEMCITABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERFERON; METALLOPROTEINASE; MINNELIDE; NATURAL PRODUCT; OMTRIPTOLIDE; PLACEBO; PROSTAGLANDIN E2; RNA POLYMERASE II; SALAZOSULFAPYRIDINE; TRIPTOLIDE; TRYPTERYGIUM WILFORDII EXTRACT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIANGIOGENIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER INHIBITION; COLITIS; DOSAGE SCHEDULE COMPARISON; DRUG POTENCY; HUMAN; LUPUS ERYTHEMATOSUS NEPHRITIS; MEDICINAL PLANT; MULTIPLE SCLEROSIS; NONHUMAN; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; RHEUMATOID ARTHRITIS; SOLID TUMOR; TRYPTERYGIUM WILFORDII;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; CARCINOMA, PANCREATIC DUCTAL; CLINICAL TRIALS AS TOPIC; DITERPENES; DRUG EVALUATION, PRECLINICAL; EPOXY COMPOUNDS; HUMANS; MEDICAL ONCOLOGY; MEDICINE, CHINESE TRADITIONAL; ORGANOPHOSPHATES; PANCREATIC NEOPLASMS; PHENANTHRENES; RESEARCH DESIGN; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84867750838     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3004956     Document Type: Review

References (25)

1. T. G. Roberts Jr., B. H. Goulart, L. Squitieri, S. C. Stallings, E. F. Halpern, B. A. Chabner, G. S. Gazelle, S. N. Finkelstein, J. W. Clark, Trends in the risks and benefits to patients with cancer participating in phase 1 clinical trials. JAMA 292, 2130-2140 (2004).
2. M. Hidalgo, Pancreatic cancer. N. Engl. J. Med. 362, 1605-1617 (2010).
3. R. Chugh, V. Sangwan, S. P. Patil, V. Dudeja, R. K. Dawra, S. Banerjee, R. J. Schumacher, B. R. Blazar, G. I. Georg, S. M. Vickers, A. K. Saluja, A preclinical evaluation of Minnelide as a therapeutic agent against pancreatic cancer. Sci. Transl. Med. 4, 156ra139 (2012).
4. R. Goldbach-Mansky, M. Wilson, R. Fleischmann, N. Olsen, J. Silverfield, P. Kempf, A. Kivitz, Y. Sherrer, F. Pucino, G. Csako, R. Costello, T. H. Pham, C. Snyder, D. van der Heijde, X. Tao, R. Wesley, P. E. Lipsky, Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: A randomized trial. Ann. Intern. Med. 151, 229-240, W49-51 (2009).
5. S. M. Kupchan, W. A. Court, R. G. Dailey Jr., C. J. Gilmore, R. F. Bryan, Triptolide and tripdiolide, novel antileukemic diterpenoid triepoxides from Tripterygium wilfordii. J. Am. Chem. Soc. 94, 7194-7195 (1972).
6. R. Graziose, M. A. Lila, I. Raskin, Merging traditional Chinese medicine with modern drug discovery technologies to find novel drugs and functional foods. Curr. Drug Discov. Technol. 7, 2-12 (2010).
7. L. J. Rather, The Genesis of Cancer: A Study in the History of Ideas (Johns Hopkins Univ. Press, Baltimore, 1978).
8. J. D. Potter, Aspirin and cancer prevention and treatment: Are we there yet? Cancer Epidemiol. Biomarkers Prev. 21, 1439-1440 (2012).
9. G. Gridley, J. K. McLaughlin, A. Ekbom, L. Klareskog, H. O. Adami, D. G. Hacker, R. Hoover, J. F. Fraumeni Jr., Incidence of cancer among patients with rheumatoid arthritis. J. Natl. Cancer Inst. 85, 307-311 (1993).
10. Q. Liu, Triptolide and its expanding multiple pharmacological functions. Int. Immunopharmacol. 11, 377-383 (2011).
11. P. A. Phillips, V. Dudeja, J. A. McCarroll, D. Borja-Cacho, R. K. Dawra, W. E. Grizzle, S. M. Vickers, A. K. Saluja, Triptolide induces pancreatic cancer cell death via inhibition of heat shock protein 70. Cancer Res. 67, 9407-9416 (2007).
12. M. B. Antonoff, R. Chugh, D. Borja-Cacho, V. Dudeja, K. A. Clawson, S. J. Skube, B. S. Sorenson, D. A. Saltzman, S. M. Vickers, A. K. Saluja, Triptolide therapy for neuroblastoma decreases cell viability in vitro and inhibits tumor growth in vivo. Surgery 146, 282-290 (2009).
13. K. A. Clawson, D. Borja-Cacho, M. B. Antonoff, A. K. Saluja, S. M. Vickers, Triptolide and TRAIL combination enhances apoptosis in cholangiocarcinoma. J. Surg. Res. 163, 244-249 (2010).
14. S. Vispé, L. DeVries, L. Créancier, J. Besse, S. Bréand, D. J. Hobson, J. Q. Svejstrup, J. P. Annereau, D. Cussac, C. Dumontet, N. Guilbaud, J. M. Barret, C. Bailly, Triptolide is an inhibitor of RNA polymerase I and II-dependent transcription leading predominantly to down-regulation of short-lived mRNA. Mol. Cancer Ther. 8, 2780-2790 (2009).
15. J. M. Fidler, K. Li, C. Chung, K. Wei, J. A. Ross, M. Gao, G. D. Rosen, PG490-88, a derivative of triptolide, causes tumor regression and sensitizes tumors to chemotherapy. Mol. Cancer Ther. 2, 855-862 (2003).
16. J. J. Kitzen, M. J. de Jonge, C. H. Lamers, F. A. Eskens, D. van der Biessen, L. van Doorn, J. Ter Steeg, M. Brandely, Ch. Puozzo, J. Verweij, Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours. Eur. J. Cancer 45, 1764-1772 (2009).
17. J. B. Sullivan, G. R. Krieger, in Clinical Environmental Health and Toxic Exposures. (Lippincott Williams & Wilkins, Philadelphia, 2001).
18. N. Mujumdar, T. N. Mackenzie, V. Dudeja, R. Chugh, M. B. Antonoff, D. Borja-Cacho, V. Sangwan, R. Dawra, S. M. Vickers, A. K. Saluja, Triptolide induces cell death in pancreatic cancer cells by apoptotic and autophagic pathways. Gastroenterology 139, 598-608 (2010).
19. S. R. Hingorani, L. Wang, A. S. Multani, C. Combs, T. B. Deramaudt, R. H. Hruban, A. K. Rustgi, S. Chang, D. A. Tuveson, Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7, 469-483 (2005).
20. K. P. Olive, M. A. Jacobetz, C. J. Davidson, A. Gopinathan, D. McIntyre, D. Honess, B. Madhu, M. A. Goldgraben, M. E. Caldwell, D. Allard, K. K. Frese, G. DeNicola, C. Feig, C. Combs, S. P. Winter, H. Ireland-Zecchini, S. Reichelt, W. J. Howat, A. Chang, M. Dhara, L. Wang, F. Rückert, R. Grützmann, C. Pilarsky, K. Izeradjene, S. R. Hingorani, P. Huang, S. E. Davies, W. Plunkett, M. Egorin, R. H. Hruban, N. Whitebread, K. McGovern, J. Adams, C. Iacobuzio-Donahue, J. Griffiths, D. A. Tuveson, Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
21. S. Gillen, T. Schuster, C. Meyer Zum Büschenfelde, H. Friess, J. Kleeff, Preoperative/neoadjuvant therapy in pancreatic cancer: A systematic review and metaanalysis of response and resection percentages. PLoS Med. 7, e1000267 (2010).
22. P. P. Provenzano, C. Cuevas, A. E. Chang, V. K. Goel, D. D. Von Hoff, S. R. Hingorani, Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429 (2012).
23. S. A. Hahn, A. B. Seymour, A. T. M. Shamsul Hoque, M. Schutte, L. T. da Costa, M. S. Redston, C. Caldas, C. L. Weinstein, A. Fischer, C. J. Yeo et al., Allelotype of pancreatic adenocarcinoma using xeno graft enrichment. Cancer Res. 55, 4670-4675 (1995).
24. S. R. Hingorani, in Drug Discovery in Pancreatic Cancer, H. Han, P. Grippo, Eds. (Springer, New York, 2010), pp. 73-93.
25. M. A. Jacobetz, D. S. Chan, A. Neesse, T. E. Bapiro, N. Cook, K. K. Frese, C. Feig, T. Nakagawa, M. E. Caldwell, H. I. Zecchini, M. P. Lolkema, P. Jiang, A. Kultti, C. B. Thompson, D. C. Maneval, D. I. Jodrell, G. I. Frost, H. M. Shepard, J. N. Skepper, D. A. Tuveson, Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 30, March 2012 (10.1136/gutjnl-2012-302529).